{
"id":"mk19_b_hm_q041",
"number":41,
"bookId":"hm",
"correctAnswer":"C",
"title":"Question 41",
"stimulus":[
{
"type":"p",
"hlId":"ceb272",
"children":[
"A 68-year-old woman is evaluated in the emergency department for abdominal and back pain and hypotension. Medical history is significant for atrial fibrillation. Medications are dabigatran and metoprolol."
]
},
{
"type":"p",
"hlId":"84a845",
"children":[
"On physical examination, temperature is 37.0 °C (98.6 °F), blood pressure is 88/60 mm Hg, pulse rate is 120/min and irregular, and respiration rate is 20/min. ",
{
"type":"reference-range-link",
"referenceRange":"Blood gases, Oxygen saturation, arterial (ambient air)",
"children":[
"Oxygen saturation"
]
},
" is 96% breathing ambient air. Cardiopulmonary examination is normal. The abdomen is tender. Ecchymoses are noted on the left flank."
]
},
{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"lab-values table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9d5fe2",
"children":[
"Laboratory studies: "
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"08837d",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Activated partial thromboplastin time",
"children":[
"Activated partial thromboplastin time"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"d228c1",
"class":"cell text l",
"children":[
"52 s"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"f9867c",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Hemoglobin, blood",
"children":[
"Hemoglobin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"5fc53a",
"class":"cell text l",
"children":[
"8.4 g/dL (84 g/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"2989c0",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Leukocyte count",
"children":[
"Leukocyte count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"19e4fd",
"class":"cell text l",
"children":[
"11,600/μL (11.6 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"fcac73",
"class":"cell text l",
"children":[
" ",
{
"type":"reference-range-link",
"referenceRange":"Platelet count",
"children":[
"Platelet count"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"61ac07",
"class":"cell text l",
"children":[
"428,000/μL (428 × 10",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"9"
]
},
"/L)"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellLeft1"
},
"children":[
{
"type":"p",
"hlId":"4ffae8",
"class":"cell text l",
"children":[
"INR"
]
}
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"className":"labValueCellRight1"
},
"children":[
{
"type":"p",
"hlId":"434144",
"class":"cell text l",
"children":[
"1.6"
]
}
]
}
]
}
]
}
]
},
{
"type":"p",
"hlId":"3fd457",
"children":[
"CT scan shows a large retroperitoneal hemorrhage."
]
}
],
"prompt":[
" ",
{
"type":"p",
"hlId":"1054f1",
"children":[
"Which of the following is the most appropriate treatment?"
]
},
" "
],
"options":[
{
"letter":"A",
"text":{
"__html":"Andexanet alfa"
}
},
{
"letter":"B",
"text":{
"__html":"4-Factor prothrombin complex concentrate"
}
},
{
"letter":"C",
"text":{
"__html":"Idarucizumab"
}
},
{
"letter":"D",
"text":{
"__html":"Plasma"
}
}
],
"keypoints":[
{
"type":"keypoint",
"hlId":"7720d3",
"children":[
"Idarucizumab is safe and effective in reversing the anticoagulant effects of dabigatran in patients with life-threatening bleeding or who require an urgent invasive procedure."
]
},
{
"type":"keypoint",
"hlId":"b95ca7",
"children":[
"Four-factor prothrombin complex concentrate or andexanet alfa can be used to reverse bleeding resulting from oral direct Xa inhibitors (apixaban, rivaroxaban, edoxaban)."
]
}
],
"exposition":[
{
"type":"p",
"hlId":"7a9861",
"children":[
"The most appropriate treatment is to administer idarucizumab (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option C"
]
},
"). This patient has a retroperitoneal hemorrhage, which is a life-threatening condition. The standard approach to patients experiencing bleeding from anticoagulants involves hemodynamic monitoring and resuscitation with fluid and blood products. Activated charcoal can be considered if the direct oral anticoagulant (DOAC) was ingested recently (<6 hours). She is taking dabigatran for atrial fibrillation, and the anticoagulant effects must be immediately reversed. Idarucizumab is a humanized monoclonal antibody fragment that binds to dabigatran and rapidly reverses its anticoagulant effects (within 1 hour). Idarucizumab is indicated to treat patients taking dabigatran who experience life-threatening bleeding or who require an urgent invasive procedure. If idarucizumab is not available, hemodialysis is another option. Up to 68% of dabigatran can be removed in 4 hours using hemodialysis; however, a rebound increase may follow because of redistribution of the drug."
]
},
{
"type":"p",
"hlId":"fefc0f",
"children":[
"Andexanet alfa is a recombinant modified factor Xa that competes for binding to factor X with the factor Xa inhibitors (apixaban, rivaroxaban, and edoxaban) (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option A"
]
},
"). For patients with life-threatening bleeding who are taking an oral direct Xa inhibitor, the American Society of Hematology suggests stopping the oral direct Xa inhibitor and considering treatment with either 4-factor prothrombin complex concentrate (4f-PCC) or andexanet alfa (off-label use for edoxaban). Because of the lack of comparative data on 4f-PCC and andexanet alfa, a preferred strategy cannot be identified. Andexanet alfa would not be useful for reversing the direct thrombin inhibition caused by dabigatran."
]
},
{
"type":"p",
"hlId":"486497",
"children":[
"4F-PCC is used to treat warfarin-associated life-threatening bleeding (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option B"
]
},
"). 4F-PCC may also be used to manage life-threatening hemorrhage in patients taking an oral direct Xa inhibitor. 4F-PCC may be less beneficial in reversing dabigatran anticoagulation than idarucizumab but might be helpful if idarucizumab is not available."
]
},
{
"type":"p",
"hlId":"b300f1",
"children":[
"Plasma does not completely reverse the effects of dabigatran, a direct thrombin inhibitor (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
"Option D"
]
},
"). Additionally, idarucizumab is a specific and much more effective intervention for patients with life-threatening bleeding secondary to dabigatran."
]
}
],
"relatedSection":"mk19_b_hm_s9_5_2_2",
"objective":{
"__html":"Treat a patient taking dabigatran who has life-threatening bleeding."
},
"references":[
[
"Cuker A, Burnett A, Triller D, et al. Reversal of direct oral anticoagulants: Guidance from the Anticoagulation Forum. Am J Hematol. 2019;94:697-709. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30916798",
"target":"_blank"
},
"children":[
"PMID: 30916798"
]
},
" doi:10.1002/ajh.25475"
]
],
"hospitalist":true,
"hvc":false,
"peerComparison":{
"A":13,
"B":16,
"C":65,
"D":6,
"E":0
},
"hlIds":[
"ceb272",
"84a845",
"9d5fe2",
"08837d",
"d228c1",
"f9867c",
"5fc53a",
"2989c0",
"19e4fd",
"fcac73",
"61ac07",
"4ffae8",
"434144",
"3fd457",
"1054f1",
"7720d3",
"b95ca7",
"7a9861",
"fefc0f",
"486497",
"b300f1"
]
}